These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 38446086)
1. Efficacy of Inclisiran in Patients Having Familial Hypercholesterolemia: Heterozygous Compared to Homozygous Trait, a Systematic Review and Meta-analysis. Rai R; Devi P; Kumar K; Naeem K; Kumar H; Kumari K; Kumar A; Kumar A; Muhammad A; Khan MS; Qadir G; Ali S; Maheshwari M; Jawwad M Crit Pathw Cardiol; 2024 Jun; 23(2):73-80. PubMed ID: 38446086 [TBL] [Abstract][Full Text] [Related]
2. Real-World Effectiveness of PCSK9 Inhibitors in Reducing LDL-C in Patients With Familial Hypercholesterolemia in Italy: A Retrospective Cohort Study Based on the AIFA Monitoring Registries. Arca M; Celant S; Olimpieri PP; Colatrella A; Tomassini L; D'Erasmo L; Averna M; Zambon A; Catapano AL; Russo P J Am Heart Assoc; 2023 Nov; 12(21):e026550. PubMed ID: 37850449 [TBL] [Abstract][Full Text] [Related]
3. Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. Raal F; Panz V; Immelman A; Pilcher G J Am Heart Assoc; 2013 Apr; 2(2):e000028. PubMed ID: 23537802 [TBL] [Abstract][Full Text] [Related]
4. Pooled Patient-Level Analysis of Inclisiran Trials in Patients With Familial Hypercholesterolemia or Atherosclerosis. Wright RS; Ray KK; Raal FJ; Kallend DG; Jaros M; Koenig W; Leiter LA; Landmesser U; Schwartz GG; Friedman A; Wijngaard PLJ; Garcia Conde L; Kastelein JJP; J Am Coll Cardiol; 2021 Mar; 77(9):1182-1193. PubMed ID: 33663735 [TBL] [Abstract][Full Text] [Related]
5. Familial hypercholesterolemia and estimation of US patients eligible for low-density lipoprotein apheresis after maximally tolerated lipid-lowering therapy. Vishwanath R; Hemphill LC J Clin Lipidol; 2014; 8(1):18-28. PubMed ID: 24528684 [TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety, and Tolerability of Inclisiran in Patients With Homozygous Familial Hypercholesterolemia: Results From the ORION-5 Randomized Clinical Trial. Raal F; Durst R; Bi R; Talloczy Z; Maheux P; Lesogor A; Kastelein JJP; Circulation; 2024 Jan; 149(5):354-362. PubMed ID: 37850379 [TBL] [Abstract][Full Text] [Related]
7. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. Raal FJ; Kallend D; Ray KK; Turner T; Koenig W; Wright RS; Wijngaard PLJ; Curcio D; Jaros MJ; Leiter LA; Kastelein JJP; N Engl J Med; 2020 Apr; 382(16):1520-1530. PubMed ID: 32197277 [TBL] [Abstract][Full Text] [Related]
8. Homozygous Familial Hypercholesterolemia in Spain: Prevalence and Phenotype-Genotype Relationship. Sánchez-Hernández RM; Civeira F; Stef M; Perez-Calahorra S; Almagro F; Plana N; Novoa FJ; Sáenz-Aranzubía P; Mosquera D; Soler C; Fuentes FJ; Brito-Casillas Y; Real JT; Blanco-Vaca F; Ascaso JF; Pocovi M Circ Cardiovasc Genet; 2016 Dec; 9(6):504-510. PubMed ID: 27784735 [TBL] [Abstract][Full Text] [Related]
9. Genetic Identification of Homozygous Familial Hypercholesterolemia by Long-Read Sequencing Among Patients With Clinically Diagnosed Heterozygous Familial Hypercholesterolemia. Chaudhry A; Trinder M; Vesely K; Cermakova L; Jackson L; Wang J; Hegele RA; Brunham LR Circ Genom Precis Med; 2023 Apr; 16(2):e003887. PubMed ID: 36960729 [TBL] [Abstract][Full Text] [Related]
10. Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor): Implications for the Efficacy of Evolocumab. Thedrez A; Blom DJ; Ramin-Mangata S; Blanchard V; Croyal M; Chemello K; Nativel B; Pichelin M; Cariou B; Bourane S; Tang L; Farnier M; Raal FJ; Lambert G Arterioscler Thromb Vasc Biol; 2018 Mar; 38(3):592-598. PubMed ID: 29284604 [TBL] [Abstract][Full Text] [Related]
11. Efficacy, Safety, and Pharmacokinetics of Inclisiran in Japanese Patients: Results from ORION-15. Yamashita S; Kiyosue A; Maheux P; Mena-Madrazo J; Lesogor A; Shao Q; Tamaki Y; Nakamura H; Akahori M; Kajinami K J Atheroscler Thromb; 2024 Jun; 31(6):876-903. PubMed ID: 38220186 [TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia: The ODYSSEY HoFH Trial. Blom DJ; Harada-Shiba M; Rubba P; Gaudet D; Kastelein JJP; Charng MJ; Pordy R; Donahue S; Ali S; Dong Y; Khilla N; Banerjee P; Baccara-Dinet M; Rosenson RS J Am Coll Cardiol; 2020 Jul; 76(2):131-142. PubMed ID: 32646561 [TBL] [Abstract][Full Text] [Related]
14. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602 [TBL] [Abstract][Full Text] [Related]
15. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study. Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335 [TBL] [Abstract][Full Text] [Related]
16. Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia. Tomlinson B; Patil NG; Fok M; Lam CWK Endocrinol Metab (Seoul); 2021 Apr; 36(2):279-295. PubMed ID: 33866776 [TBL] [Abstract][Full Text] [Related]
17. Rationale and design of two trials assessing the efficacy, safety, and tolerability of inclisiran in adolescents with homozygous and heterozygous familial hypercholesterolaemia. Reijman MD; Schweizer A; Peterson ALH; Bruckert E; Stratz C; Defesche JC; Hegele RA; Wiegman A Eur J Prev Cardiol; 2022 Jul; 29(9):1361-1368. PubMed ID: 35175352 [TBL] [Abstract][Full Text] [Related]
19. Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥ 70 mg/dl despite maximal tolerated cholesterol lowering therapy. Glueck CJ; Shah P; Goldenberg N; Prince M; Lee K; Jetty V; Kumar A; Goldenberg M; Wang P Lipids Health Dis; 2016 Mar; 15():55. PubMed ID: 26968977 [TBL] [Abstract][Full Text] [Related]
20. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Brandts J; Dharmayat KI; Vallejo-Vaz AJ; Azar Sharabiani MT; Jones R; Kastelein JJP; Raal FJ; Ray KK Atherosclerosis; 2021 May; 325():46-56. PubMed ID: 33901739 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]